Streetbeat News

Earnings

ACOR

AIH

SLP

In Wednesday's after-market session, several healthcare stocks showed notable movements. Aesthetic Medical Intl, Kineta, Simulations Plus, Bolt Biotherapeutics, Eiger BioPharmaceuticals, and Kodiak Sciences were among the gainers, with Simulations Plus and Kodiak Sciences releasing their Q2 and Q4 earnings reports, respectively. On the losing side, Connect Biopharma Holdings, Acorda Therapeutics, Innate Pharma, Qilian Intl Holding Group, Universe Pharmaceuticals, and Helius Medical Technologies experienced declines, with Acorda Therapeutics and Helius Medical Technologies also releasing their Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 8:31 pm

CASA

CVV

GVP

SLNH

WISA

In Wednesday's after-market session, 12 Information Technology stocks showed significant movements. WiSA Technologies, Smith Micro Software, GSE Systems, CVD Equipment, SkyWater Technology, and Soluna Holdings were among the gainers, with WiSA Technologies leading with a 16.7% increase. On the downside, Casa Systems, X3 Holdings, Sobr Safe, Movano, AEye, and Core Scientific experienced declines, with Casa Systems dropping the most by 9.6%. Notably, GSE Systems, CVD Equipment, and Soluna Holdings' movements were influenced by their recent Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 8:31 pm

SLP

Simulations Plus has provided its financial outlook for FY24, projecting EPS in the range of $0.66-$0.68, closely aligning with the estimated $0.66. The company anticipates revenue to be between $66M-$69M, which brackets the estimated $67.160M.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 8:30 pm

ABBV

AbbVie projects its Q1 2024 adjusted diluted EPS to be in the range of $2.18-$2.22, accounting for acquired IPR&D and milestones expense of $164M on a pre-tax basis. The company's reported GAAP earnings for Q1 2024 will include these expenses, as disclosed in an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 8:27 pm

ABBV

AbbVie Inc has announced that its adjusted non-GAAP earnings for Q1 of 2024 will include an acquired IPR&D and milestones expense of $164M on a pre-tax basis. Consequently, the company has adjusted its 2024 diluted EPS guidance range to $10.97-$11.17, factoring in the impact of these expenses.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 8:26 pm

LEVI

Levi Strauss shares surged following the announcement of stronger-than-anticipated Q1 financial outcomes and an upward revision of its 2024 adjusted EPS forecast.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 8:24 pm

BMTX

BM Technologies (BMTX) reported Q4 losses of $(0.28) per share, missing the $(0.25) estimate, and sales of $14.86M, missing the $14.95M estimate. This represents a decrease in performance compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 8:19 pm

BNL

Broadstone Net Lease (BNL) invested $40.1 million in Q1 2024, including development fundings and capital expenditures, primarily for a distribution facility in Sarasota, Florida. The facility, leased to UNFI for 15 years, is expected to open in Q3 2024 with a 7.2% stabilized yield. BNL has $282.7 million in committed investments and sold 37 healthcare properties for $251.7 million. The portfolio was 99.2% leased, with 99.0% of base rents collected.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 8:13 pm

SLP

Simulations Plus forecasts its FY24 earnings per share (EPS) to be in the range of $0.66-$0.68, compared to the estimated $0.66. The company also projects its revenue to be between $66 million and $69 million, versus the estimated $67.160 million.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 8:11 pm

LEVI

Levi Strauss & Co has increased its adjusted EPS guidance for 2024 from the range of $1.15-$1.25 to $1.17-$1.27, surpassing the estimated $1.21.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 8:10 pm